{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-105182","form_type":"8-K","ticker":"LQDA","cik":"0001819576","company_name":"Liquidia Corp","filed_at":"2024-10-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.818024+00:00","generated_at":"2026-05-30T22:46:32.614168+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Liquidia expands L606 license to Europe/Japan; gets nebulizer rights; $3.5M upfront, up to $157.75M milestones","bullets":["Expanded exclusive license to include Europe, Japan, and other key markets outside North America; $3.5M upfront payment.","Up to $157.75M in additional milestone payments: $7.75M development + $150M commercial sales milestones outside North America.","Obtained exclusive rights to Pharmosa's next-generation smart-technology nebulizers for use with L606.","L606 pivotal study in PH-ILD expected to start later this year; positive EMA scientific advice received.","Open-label safety study shows L606 tolerated up to 378 mcg twice daily; supports twice-daily dosing via breath-actuated nebulizer."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-105182","json":"https://secwatch.observer/filing/0001104659-24-105182.json","markdown":"https://secwatch.observer/filing/0001104659-24-105182.md","text":"https://secwatch.observer/filing/0001104659-24-105182.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1819576/000110465924105182/0001104659-24-105182-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1819576/000110465924105182/tm2425377d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T22:46:32.614168+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}